natgillin/translations-raw huggingface dataset:
In patients who remained on therapy within five days of bypass graft surgery, the event rate was 9.6% for clopidogrel plus ASA, and 6.3% for placebo plus ASA. 
U bolesnika koji su terapiju nastavili primati i unutar 5 dana do ugrađivanja premosnice, stopa krvarenja bila je 9,6% za klopidogrel uz ASK, odnosno 6,3% za placebo uz ASK.
The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. 
Aktivni metabolit klopidogrela selektivno inhibira vezanje adenozin difosfata (ADP) za njegov receptor P2Y12 na trombocitima te posljedično ADP-om posredovano aktiviranje kompleksa GPIIb/IIIa, inhibirajući tako agregaciju trombocita.
The decrease was associated with a 39% (loading dose) and 21% (maintenance dose) reduction of inhibition of platelet aggregation. 
Smanjenje je bilo povezano s oslabljenom inhibicijom agregacije trombocita od 39% (udarna doza) i 21% (doza održavanja).
The primary endpoint (the combined incidence of CV death, MI, stroke and BARC bleeding grade ≥2 at 12 months) was met showing non-inferiority. 
Primarna mjera ishoda (kombinirana incidencija kardiovaskularne smrti, infarkta miokarda, moždanog udara i BARC stupnja krvarenja ≥ 2 u 12 mjeseci) je ostvarena te je pokazala neinferiornost.
• You should tell your doctor if a surgery (including dental) is planned. 
Dok uzimate Clopidogrel Krka d.d.: - Obavijestite svog liječnika ako planirate kirurški zahvat (uključujući stomatološke zahvate).
No clinically significant pharmacodynamic interactions were observed when clopidogrel was coadministered with atenolol, nifedipine, or both atenolol and nifedipine. 
Nisu primijećene klinički značajne farmakodinamičke interakcije pri istodobnoj primjeni klopidogrela i atenolola, odnosno nifedipina, ili klopidogrela i ta dva lijeka zajedno.
Serum sickness, anaphylactoid reactions cross-reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*, insulin autoimmune syndrome, which can lead to severe hypoglycemia, particularly in patients with HLA DRA4 subtype (more frequent in the Japanese population)* 
Poremećaji imunološkog sustava serumska bolest, anafilaktoidne reakcije, križno reaktivna preosjetljivost na lijekove iz skupine tienopiridina (kao što su tiklopidin, prasugrel) (vidjeti dio 4.4)*, autoimuni inzulinski sindrom koji može dovesti do teške hipoglikemije, osobito u bolesnika s podtipom HLA DRA4 (češći u japanskoj populaciji)*
• Adult patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). 
- odraslih bolesnika koji boluju od akutnog koronarnog sindroma: - Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda), uključujući bolesnike koji se podvrgavaju ugradnji stenta nakon perkutane koronarne intervencije, u kombinaciji s acetilsalicilatnom kiselinom (ASK).
In patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily). 
Bolesnici s akutnim koronarnim sindromom: - Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda): liječenje klopidogrelom treba započeti s jednokratnom udarnom dozom od 300 mg, a zatim nastaviti sa 75 mg jedanput dnevno (uz acetilsalicilatnu kiselinu (ASK) 75 mg do 325 mg dnevno).
Co-administration of heparin had no effect on the inhibition of platelet aggregation induced by clopidogrel. 
Istodobna primijena heparina nije imala učinak na inhibiciju agregacije trombocita induciranu klopidogrelom.
You should specifically tell your doctor if you take - medicines that may increase your risk of bleeding such as: o oral anticoagulants, medicines used to reduce blood clotting, o a non-steroidal anti-inflammatory medicine, usually used to treat painful and/or inflammatory conditions of muscle or joints, o heparin or any other injectable medicine used to reduce blood clotting, o ticlopidine, other antiplatelet agent, o a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression, - omeprazole or esomeprazole, medicines to treat upset stomach, - fluconazole or voriconazole, medicines to treat fungal infections, - efavirenz, a medicine to treat HIV (human immunodeficiency virus) infections, 
Posebno je važno obavijestiti liječnika ako uzimate - lijekove koji mogu povećati rizik od krvarenja, na primjer: - oralne antikoagulanse, lijekove koji smanjuju zgrušavanje krvi, - nesteroidne protuupalne lijekove, koji se obično primjenjuju za liječenje bolnih i/ili upalnih stanja mišića ili zglobova, - heparin ili bilo koji drugi lijek koji se daje putem injekcije za smanjivanje zgrušavanja krvi, - tiklopidin, drugi antitrombocitni lijek, - selektivne inhibitore ponovne pohrane serotonina (uključujući, ali ne ograničeno na fluoksetin ili fluvoksamin), lijekove koji se obično koriste za liječenje depresije, - omeprazol ili esomeprazol, lijekove za smanjenje želučanih tegoba, - flukonazol ili vorikonazol, lijekove koji se primjenjuju za liječenje gljivičnih infekcija, - efavirenz, lijek koji se primjenjuje za liječenje HIV (virus humane imunodeficijencije) infekcija, - karbamazepin, lijek koji se primjenjuje za liječenje nekih oblika epilepsije, - moklobemid, lijek za liječenje depresije, - repaglinid, lijek za liječenje dijabetesa,
TOPIC (Timing Of Platelet Inhibition after acute Coronary syndrome) This randomized, open-label trial included ACS patients requiring PCI. 
Timing of Platelet Inhibition after Acute Coronary Syndrome) Ovo randomizirano, otvoreno ispitivanje uključivalo je bolesnike s akutnim koronarnim sindromom u kojih je bila potrebna perkutana koronarna intervencija (PCI).
Pharmacogenetics: In patients who are poor CYP2C19 metabolisers, clopidogrel at recommended doses forms less of the active metabolite of clopidogrel and has a smaller effect on platelet function. 
Farmakogenetika: u bolesnika koji su slabi CYP2C19 metabolizatori, kod preporučenih doza klopidogrela stvara se manja količina aktivnog metabolita te ima manji učinak na funkciju trombocita.
The efficacy of clopidogrel was observed independently of the dose of ASA (75-325 mg once daily). 
Djelotvornost klopidogrela nije ovisila o dozi ASK (75 do 325 mg jedanput dnevno).
Manufacturer: 
Proizvođač
is taken by adults to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death). 
Clopidogrel Krka d.d. uzimaju odrasli za sprječavanje stvaranja krvnih ugrušaka (tromba) u otvrdnutim krvnim žilama (arterijama), a taj poremećaj zove se aterotromboza i može dovesti do aterotrombotičkih događaja (kao što su moždani udar, srčani udar ili smrt).
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36 % odds reduction in favor of clopidogrel (95% CI: 24, 47%; p < 0.001), mainly related to a reduction in occluded infarct-related arteries. 
Petnaest posto (15,0%) bolesnika u skupini s klopidogrelom i 21,7% u skupini s placebom dostigli su primarni ishod, što predstavlja apsolutno smanjenje od 6,7% i smanjenje izgleda (od engl. odds reduction) od 36% u korist klopidogrela (95% CI: 24, 47%; p<0,001), većinom povezano sa smanjenjem okluzije arterija povezanih s infarktom.
Titanium dioxide (E171)Red iron oxide (E172) Yellow iron oxide (E172) Talc 
Film ovojnica: poli(vinilni alkohol) titanijev dioksid (E171) željezov oksid, crveni (E172) željezov oksid, žuti (E172) talk makrogol 3000
You should not breast-feed while taking this medicine. 
Dok uzimate ovaj lijek, ne biste smjeli dojiti.
The dose of 0.2 mg/kg achieved the mean percent inhibition of 49.3% (5 µM ADP-induced platelet aggregation) which was comparable to that of adults taking clopidogrel 75 mg/day. 
S dozom od 0,2 mg/kg postignut je prosječni postotak inhibicije od 49,3% (5 µM ADP-om inducirane agregacije trombocita), što je usporedivo s postotkom u odraslih koji uzimaju klopidogrel u dozi od 75 mg/dnevno.
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors, or selective serotonin reuptake inhibitors (SSRIs), or other medicinal products associated with bleeding risk such as pentoxifylline (see section 4.5). 
Kao i u slučaju drugih antitrombocitnih lijekova, klopidogrel s oprezom treba davati bolesnicima koji su izloženi povećanom riziku od krvarenja zbog povrede, kirurških zahvata ili drugih patoloških stanja te bolesnicima koji se liječe s ASK, heparinom, inhibitorima glikoproteina IIb/IIIa ili nesteroidnim protuupalnim lijekovima (NSAIL), uključujući Cox-2 inhibitore ili selektivne inhibitore ponovne pohrane serotonina (SSRI) ili druge lijekove povezane s rizikom od krvarenja kao što je pentoksifilin (vidjeti dio 4.5).
Patients should be evaluated for history of hypersensitivity to thienopyridines (such as clopidogrel, ticlopidine, prasugrel) since cross-reactivity among thienopyridines has been reported (see section 4.8). 
Kod bolesnika treba procijeniti prethodnu preosjetljivost na tienopiridine u povijesti bolesti (kao što su klopidogrel, tiklopidin, prasugrel) budući da je zabilježena ukrižena reaktivnost među tienopiridinima (vidjeti dio 4.8).
Some other medicines may influence the use of Clopidogrel Krka d.d. 
Neki lijekovi mogu utjecati na djelovanje Clopidogrela Krka d.d. i obratno.
The mean age was 71 years, 41.6% of patients were ≥75 years. 
Prosječna dob iznosila je 71 godinu, uz 41,6%
• If you cut or injure yourself, it may take longer than usual for bleeding to stop. 
- Ako se porežete ili ozlijedite, možda će biti potrebno više vremena da se krvarenje zaustavi.
Clopidogrel significantly reduced the incidence of new ischaemic events (combined end point of myocardial infarction, ischaemic stroke and vascular death) when compared to ASA. 
Pri usporedbi s ASK, klopidogrel je značajno smanjio incidenciju novih ishemijskih događaja (kombinirani ishod infarkta miokarda, ishemijskog moždanog udara i vaskularne smrti).
Due to the risk of increased plasma concentrations, concomitant administration of clopidogrel and drugs primarily cleared by CYP2C8 metabolism (e.g., repaglinide, paclitaxel) should be undertaken with caution (see section 4.4). 
Zbog rizika od povećanja koncentracija u plazmi, potreban je oprez pri istodobnoj primjeni klopidogrela i lijekova koji se primarno metaboliziraju putem CYP2C8 (npr. repaglinid, paklitaksel) (vidjeti dio 4.4).
Rare side effects (may affect up to 1 in 1000 people): Vertigo, enlarged breasts in males. 
Rijetke nuspojave (mogu se javiti u manje od 1 na 1000 osoba): vrtoglavica, povećanje grudi u muškaraca.
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel Krka d.d.. 
Ako se bilo što od navedenog odnosi na Vas, ili niste sigurni, obratite se svom liječniku prije uzimanja Clopidogrela Krka d.d.
De-escalation of P2Y12 Inhibitor Agents in ACS 
De-eskalacija P2Y12 inhibitora (prelazak sa potentnijeg na slabiji P2Y12 inhibitor) kod akutnog koronarnog sindroma
Strokes occurred in 296 (7.8%) patients receiving clopidogrel + ASA and 408 (10.8%) patients receiving placebo + ASA (relative risk reduction, 28.4%; 95% CI, 16.8% to 38.3%; p=0.00001). 
Moždani udar doživjelo je 296 (7,8%) bolesnika koji su primali klopidogrel + ASK te 408 (10,8%) bolesnika koji su primali placebo + ASK (relativno smanjenje rizika od 28,4%; 95% CI, 16,8% do 38,3%; p=0,00001).
The clinical benefit provided by the more potent P2Y12 inhibitors, ticagrelor and prasugrel, in their pivotal studies is related to a significant reduction in recurrent ischaemic events (including acute and subacute stent thrombosis (ST), myocardial infarction (MI), and urgent revascularization). 
Klinička korist koju su u pivotalnim ispitivanjima pokazali potentniji inhibitori P2Y12, tikagrelor i prasugrel, povezana je sa značajnim smanjenjem rekurentnih ishemijskih događaja (uključujući akutnu i subakutnu trombozu stenta, infarkt miokarda i hitnu revaskularizaciju).
A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metaboliser groups (ultrarapid, extensive, intermediate and poor), evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg/day and 600 mg followed by 150 mg/day, each for a total of 5 days (steady state). 
U križnoj studiji na 40 zdravih osoba, po 10 iz svake skupine CYP2C19 metabolizatora (ultrabrzi, brzi, umjereni i slabi), procijenjen je farmakokinetički i antitrombocitni odgovor upotrebom doze od 300 mg, nakon čega je slijedila doza od 75 mg/dan te doze od 600 mg, nakon čega je slijedila doza od 150 mg/dan, u trajanju od ukupno 5 dana (stanje dinamičke ravnoteže).
Patients received clopidogrel (75 mg/day, n=22,961) or placebo (n=22,891), in combination with ASA (162 mg/day), for 28 days or until hospital discharge. 
Bolesnici su primali klopidogrel (75 mg dnevno, n=22 961) ili placebo (n=22 891), u kombinaciji s ASK (162 mg dnevno), u trajanju do 28 dana ili do otpusta iz bolnice.
Caution is required in patients treated concomitantly with clopidogrel and CYP2C8 substrate medicinal products (see section 4.5). 
Potreban je oprez u bolesnika koji se istodobno liječe klopidogrelom i lijekovima koji su supstrati CYP2C8 (vidjeti dio 4.5).
Prevention of atherothrombotic and thromboembolic events in atrial fibrillation In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. 
U odraslih bolesnika s fibrilacijom atrija koji imaju najmanje jedan faktor rizika za krvožilne događaje, nisu podobni za terapiju antagonistima vitamina K (VKA) te imaju nizak rizik od krvarenja, klopidogrel je indiciran u kombinaciji s ASK za prevenciju aterotrombotičkih i tromboembolijskih događaja, uključujući moždani udar.
Therapeutic experience with clopidogrel is limited in patients with renal impairment. 
Terapijsko iskustvo s klopidogrelom u bolesnika s narušenom funkcijom bubrega je ograničeno.
The population included 27.8% women, 58.4% patients ≥ 60 years (26% ≥ 70 years) and 54.5% patients who received fibrinolytics. 
bolesnika ≥60 godina (26% ≥70 godina) i 54,5% bolesnika koji su primali fibrinolitike.
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day. 
Nakon ponovljenih doza od 75 mg klopidogrela dnevno, inhibicija ADP-om inducirane agregacije trombocita bila je niža (25%) u ispitanika s teško narušenom funkcijom bubrega (klirens kreatinina od 5 do 15 ml/min), u usporedbi sa zdravim ispitanicima, iako je produljenje vremena krvarenja bilo slično onom zabilježenom u zdravih bolesnika koji su primali 75 mg klopidogrela dnevno.
- ST segment elevation acute myocardial infarction: clopidogrel should be given as a single daily dose of 75 mg initiated with a 300 mg loading dose in combination with ASA and with or without thrombolytics. 
- Akutni infarkt miokarda s elevacijom ST-segmenta: liječenje klopidogrelom provodi se jednom dnevnom dozom od 75 mg, a započinje udarnom dozom od 300 mg u kombinaciji s ASK te sa ili bez trombolitika.
• Hypersensitivity to the active substance or to any of the excipients listed in section 2 or section 
- Preosjetljivost na djelatnu tvar ili neku od pomoćnih tvari navedenih u dijelu 2 ili dijelu 6.1.
• Paediatric population Clopidogrel should not be used in children because of efficacy concerns (see section 5.1). 
- Pedijatrijska populacija Klopidogrel se ne primjenjuje u djece zbog nedovoljnih podataka o djelotvornosti (vidjeti dio
An appropriate dose regimen for this patient population has not been established in clinical outcome trials. 
U kliničkim studijama nije utvrđen odgovarajući režim doziranja za ovu populaciju bolesnika.
Patients should be told that it might take longer than usual to stop bleeding when they take clopidogrel (alone or in combination with ASA), and that they should report any unusual bleeding (site or duration) to their physician. 
Bolesnicima koji uzimaju klopidogrel (kao monoterapiju ili u kombinaciji s ASK) potrebno je objasniti da će krvarenje možda trajati dulje nego obično i da moraju obavijestiti liječnika o bilo kakvom neočekivanom krvarenju (s obzirom na mjesto i trajanje krvarenja).
Intracranial bleeding (some cases were reported with fatal outcome), headache, paraesthesia, dizziness 
Poremećaji živčanog sustava intrakranijalno krvarenje (prijavljeni su neki slučajevi s fatalnim ishodom) glavobolja, parestezija, omaglica poremećaj okusa, ageuzija
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel Krka d.d. 
Ako ste imali jake bolove u prsištu (nestabilna angina ili srčani udar), liječnik Vam u početku liječenja može jednokratno dati 300 mg Clopidogrela Krka d.d. (4 tablete od po 75 mg).
The concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.5). 
Ne preporučuje se istodobna primjena klopidogrela i drugih oralnih antikoagulansa, jer to može pojačati intenzitet krvarenja (vidjeti dio 4.5).
No new safety concerns were noted during this long-term follow-up. 
Nisu primjećeni problemi vezani uz sigurnost primjene lijeka tijekom ove dugotrajne nastavne studije.
plus acetylsalicylic acid if you cannot take ‘oral anticoagulants' and you do not have a risk of major bleeding. 
Liječnik Vam treba propisati Clopidogrel Krka d.d. i acetilsalicilatnu kiselinu ako ne možete uzimati oralne antikoagulanse te nemate rizik od velikog krvarenja.
Common side effects (may affect up to 1 in 10 people): Diarrhoea, abdominal pain, indigestion or heartburn. 
Česte nuspojave (mogu se javiti u manje od 1 na 10 osoba): proljev, bol u trbuhu, probavne tegobe ili žgaravica.
Other concomitant therapy: Since clopidogrel is metabolised to its active metabolite partly by CYP2C19, use of medicinal products that inhibit the activity of this enzyme would be expected to result in reduced drug levels of the active metabolite of clopidogrel. 
Ostala istodobna terapija: s obzirom da se klopidogrel do svog aktivnog metabolita djelomično metabolizira enzimom CYP2C19, očekuje se da će primjena lijekova koji inhibiraju aktivnost ovog enzima rezultirati smanjenim razinama aktivnog metabolita klopidogrela.
This was consistent across subgroups of patients defined by baseline characteristics, and type of fibrinolytic or heparin therapy. 
Sukladni podaci dobiveni su i u podskupinama bolesnika definiranim prema početnim karakteristikama i tipu terapije fibrinoliticima ili heparinom.
to help prevent blood clots and reduce the risk of these severe events because: - You have a condition of hardening of arteries (also known as atherosclerosis), and - You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease. 
Clopidogrel Krka d.d. Vam je propisan za sprječavanje stvaranja krvnih ugrušaka i smanjivanje opasnosti od ovih ozbiljnih događaja jer: - imate otvrdnuće arterija (koje se još zove ateroskleroza) te - ste već imali srčani udar, moždani udar ili imate stanje koje se zove bolest perifernih arterija, - ste imali teški oblik boli u prsištu, poznat pod nazivom “nestabilna angina” ili “infarkt miokarda” (srčani udar).
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme, acute generalised exanthematous pustulosis (AGEP)), angioedema, drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous or exfoliative, urticaria, eczema, lichen planus 
bulozni dermatitis (toksična epidermalna nekroliza, Stevens Johnsonov sindrom, erythema multiforme, akutna generalizirana egzantematozna pustuloza (AGEP)), angioedem, sindrom preosjetljivosti izazvan lijekom, osip uzrokovan lijekom s eozinofilijom i sistemskim simptomima (engl.
• If you suffer from severe liver disease. 
- Ako imate bolest bubrega ili jetre.
Patients were randomised to clopidogrel 75 mg/day or ASA 325 mg/day, and were followed for 1 to 3 years. 
Bolesnici su randomizirani u skupine koje su dnevno primale 75 mg klopidogrela ili 325 mg acetilsalicilatne kiseline te su praćeni od 1 do 3 godine.
As a precaution concomitant use of strong or moderate CYP2C19 inhibitors should be discouraged (see section 4.5 for a list of CYP2C19 inhibitors, see also section 5.2). 
Kao mjera opreza, ne preporučuje se istodobna primjena lijekova koji su jaki ili umjereni inhibitori CYP2C19 (za popis inhibitora CYP2C19 vidjeti dio 4.5, također vidjeti dio 5.2).
If you forget for more than 12 hours, simply take the next single dose at the usual time. 
Ukoliko se ne sjetite propuštene doze u roku od 12 sati, uzmite sljedeću dozu u uobičajeno vrijeme.
Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP. 
Klopidogrel, također, inhibira agregaciju trombocita induciranu drugim agonistima, pored ADP-a i to blokiranjem pojačavanja aktivacije trombocita oslobođenim ADP-om.
Acute liver failure, hepatitis, abnormal liver function test 
Poremećaji jetre i žuči akutno zatajenje jetre, hepatitis, abnormalni nalazi jetrene funkcije
(98.1%) in the de-escalated DAPT group and 318 patients (98.5%) in the unchanged DAPT group. 
Nakon godine dana provedeno je praćenje 316 bolesnika (98,1%) u skupini sa de-eskaliranim DAPT-om i 318 bolesnika (98,5%) u skupini sa nepromijenjenim DAPT-om.
• Within less than 12 hours after regular scheduled time: patients should take the dose immediately and then take the next dose at the regular scheduled time. 
Propuštena doza: - Ako je prošlo manje od 12 sati nakon uobičajenog termina uzimanja lijeka: bolesnik treba odmah uzeti dozu, a sljedeću dozu treba uzeti prema uobičajenom rasporedu.
If you stop taking Clopidogrel Krka d.d. 
Ako prestanete uzimati Clopidogrel Krka d.d.